Atara Biotherapeutics Inc
ATRA
Company Profile
Business description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Contact
2380 Conejo Spectrum Street
Suite 200
Thousand OaksCA91320
USAT: +1 805 623-4211
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
159
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,967.27 | 74.66 | 0.95% |
| DAX 40 | 21,479.25 | 67.72 | 0.32% |
| Dow JONES (US) | 44,565.07 | 408.34 | 0.92% |
| FTSE 100 | 8,575.89 | 10.69 | 0.12% |
| HKSE | 20,066.19 | 365.63 | 1.86% |
| NASDAQ | 20,053.68 | 44.34 | 0.22% |
| Nikkei 225 | 39,931.98 | 26.89 | -0.07% |
| NZX 50 Index | 13,024.70 | 35.38 | -0.27% |
| S&P 500 | 6,118.71 | 32.34 | 0.53% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,252.63 | 22.46 | 0.70% |